Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT 333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C Vírus Infection witb Cirrhosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-004111-37-HU

Enrollment

Registered

2014-09-24

Start date

2014-10-22

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 17.0 Level: PT Classification code 10019744 Term: Hepatitis C System Organ Class: 10021881 - Infections and infestations

Interventions

Product Name: ABT-450/r/ABT-267+ABT-333 Pharmaceutical Form: Other descriptive name: ABT-450 ABT-450 Concentration unit: mg milligram(s) Concentration number: 75- INN or Proposed INN: RITONAVIR CAS N

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Hungary

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026